GEN Exclusives

More »

GEN News Highlights

More »
Jul 1, 2010

Sanofi-Aventis Acquires TargeGen and Inks Partnership with JDRF

  • Sanofi-Aventis is taking over TargeGen, a developer of small molecule kinase inhibitors. The company separately entered a research agreement with the Juvenile Diabetes Research Foundation (JDRF) focused on type 1 diabetes.

    The ultimate purchase price for TargeGen will depend on the achievement of certain milestones with the potential of reaching $560 million. The transaction is expected to close in the third quarter of this year.

    Formed in 2001, TargeGen's most advanced drug candidate, TG101348, completed a Phase I study in October 2009. It is being developed for the treatment of patients with myeloproliferative diseases including primary and secondary myelofibrosis (MF) and polycythemia vera (PV). There are currently no approved drugs for either disease.

    The molecule is an oral, potent, and highly selective JAK2 kinase inhibitor, according to TargeGen. Preliminary data from a 59-patient trial involving the treatment of MF patients with TG101348 was presented at the American Society of Hematology Conference in New Orleans in December 2009.

    Along with preclinical data, the company says that TG101348 has shown that, in addition to the treatment of certain myeloproliferative disorders, it may also have potential utility in the treatment of certain forms of hematological malignancies like leukemia and lymphoma as weel as other blood disorders.

    “Sanofi-aventis brings significant strength and resources to the continued development and potential commercialization of TG101348," says Peter G. Ulrich, president, CEO, and co-founder of TargeGen. “With their global focus on oncology and long-term commitment to this patient population, we are confidant they will maximize the treatment potential of TG101348 across multiple clinical indications.”

    Additionally, sanofi-aventis’ partnership with JDRF gives it options to the intellectual property developed by researchers who receive funding through the program. Both parties will provide financial support to academic investigators and nonprofit medical research organizations to conduct projects in regeneration and immune therapy.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »